¡¡ |
Morning Scientific Symposium |
ÁÂÀå: °ÁøÇü (¼¿ï¼º¸ðº´¿ø) |
08:50~09:30 |
A paradigm shift in ALK+NSCLC first-line treatment : clinical experience of ALUNBRIG¢ç |
±èŹΠ(¼¿ï´ëº´¿ø) |
¡¡ |
Plenary Session¡¡¡¡ |
¡¡ |
Diagnosis & monitoring of lung cancer¡¡ |
ÁÂÀå: ±è½ÂÁØ (¼¿ï¼º¸ðº´¿ø) |
09:30~09:50 |
Non-invasive biomarkers in lung cancer management |
¹ÚÂù±Ç (¿©Àǵµ¼º¸ðº´¿ø) |
09:50~10:10 |
Recent progress of lung cancer screening¡¡ |
Àü°æ³à (â¿ø°æ»ó´ëº´¿ø) |
10:10~10:30 |
New WHO classification of lung tumors |
±è·ç½Ã¾Æ (ÀÎÇϴ뺴¿ø) |
¡¡ |
Treatment of lung cancer |
ÁÂÀå: ±è»óÀ§ (¼¿ï¾Æ»êº´¿ø) |
10:30~10:50 |
Surgical role in the era of perioperative immune checkpoint inhibitor |
±èÈ«°ü (»ï¼º¼¿ïº´¿ø) |
10:50~11:10 |
New data of precision oncology practice from WCLC 2020 |
¹Î¿µÁÖ (¿ï»ê´ëº´¿ø) |
11:10~11:30 |
Updated clinical trial data of immuno-oncology |
±èÇý·Ã (¼¼ºê¶õ½ºº´¿ø) |
11:30~11:40 |
Q&A¡¡ |
¡¡ |
Scientific Symposium ¡¡ |
ÁÂÀå: À̱âÇü (ÃæºÏ´ëº´¿ø) |
11:40~12:30 |
Beyond becoming a SOC in mNSCLC treatment, Pembrolizumab now opens a new era of More TOMORROWs |
À̼¼ÈÆ (»ï¼º¼¿ïº´¿ø) |
12:30~13:00 |
Coffee Break |
¡¡ |
Room A |
Room B |
Room C |
Parallel Session |
Multidisciplinary: Expanding indication of local therapy in lung cancer
ÁÂÀå: ±è¿¬½Ç (¼¿ï¼º¸ðº´¿ø)
|
¡¡ |
Imaging and Screening
ÁÂÀå: ±èÀ±Çö (Àü³²´ëº´¿ø)
|
13:00~13:20 Radiofrequency ablation as lung cancer treatment
Áø°ø¿ë (ÀüºÏ´ëº´¿ø) |
¡¡ |
13:00~13:25 Screening and early detection-lung cancer screening programs
ÀÓÀ籤 (°æºÏ´ëº´¿ø) |
13:20~13:40 Radiotherapy in early stage and oligomers
ÀÓäȫ (°í·Á´ë¾È»êº´¿ø) |
13:25~13:50 Screening and early detection -risk modelling and artificial intelligence
³²ÁÖ° (¼¿ï´ëº´¿ø) |
13:40~14:00 Limited surgery not limited to local disease
±èÇö±¸ (°í·Á´ë±¸·Îº´¿ø) |
13:50~14:15 Screening and early detection -radiological risk stratification
ÀÌÁ¾Àº (Àü³²´ëº´¿ø) |
14:00~14:20 Discussion |
14:15~14:20 Discussion |
Advanced NSCLC
ÁÂÀå: ½Éº´¿ë (¼ººó¼¾Æ®º´¿ø)
|
Pulmonology
ÁÂÀå: Àå½ÂÈÆ (ÇѸ²´ë¼º½Éº´¿ø)
|
Pathology & Biomarker Discovery
ÁÂÀå: À̰DZ¹ (±¹¸³¾Ï¼¾ÅÍ)
|
14:20~14:50 Immunotherapy
¹Ú°Ç¿í (°è¸í´ëµ¿»êº´¿ø) |
14:20~14:40 Something new in Palliative and Supportive Care
¿©Ã¢µ¿ (ÀºÆò¼º¸ðº´¿ø) |
14:20~14:40 The New WHO Classification of Lung Tumors
½ÉÈ¿¼· (¼¼ºê¶õ½ºº´¿ø) |
14:40~15:00 Tumor Biology and Advances in Omics
ÀÌÁ¤Àº (Ãæ³²´ëº´¿ø) |
14:40~15:00 Getting All NSCLCs Genotyped: How Can We Get to 100%?
±èÅÂÁ¤ (¿©Àǵµ¼º¸ðº´¿ø) |
14:50~15:20 New data from rare EGFR Alterations
ÀÌÀ±±Ô (°ºÏ»ï¼ºº´¿ø) |
15:00~15:20 Technological Advances in Diagnostics for Lung Cancer
±èÇý·Ã (¿øÀڷº´¿ø) |
15:00~15:20 Advances in Biomarkers for Immune Checkpoint Blockade and Targeted Therapy in Non Small Cell Lung Carcinoma
ÃÖÀ±¶ó (»ï¼º¼¿ïº´¿ø) |
15:20~15:30Discussion ¡¡ |
15:20~15:30 Discussion |
15:20~15:30 Discussion |
15:30~16:00 Coffee Break |
Thoracic malignancies
ÁÂÀå: ÀÌ´ëÈ£ (¼¿ï¾Æ»êº´¿ø)
|
Thoracic Surgical Oncology
ÁÂÀå: °Ã¢Çö (¼¿ï´ëº´¿ø)
|
Update in Radiation Oncology
ÁÂÀå: ¹®¼ºÈ£ (±¹¸³¾Ï¼¾ÅÍ)
|
16:00~16:20 SCLC
ÀÓ¼±¹Î (¼¼ºê¶õ½ºº´¿ø) |
16:00~16:20 - Therapeutic strategies for metachronous multiple primary lung cancer
- Prognostic factors and strategies for metachronous second primary lung cancer
Á¶Á¾È£ (»ï¼º¼¿ïº´¿ø) |
16:00~16:20 Radiotherapy for LA-NSCLC
¼ÛÃ¢ÈÆ (ºÐ´ç¼¿ï´ëº´¿ø) |
16:20~16:45 Thymic Malignacy/Mesothelioma
¹Ú¼¼ÈÆ (»ï¼º¼¿ïº´¿ø) |
16:20~16:40 - Characterization and classification of oligometastatic disease
- Surgery as a component of local consolidative therapy
À̱ٵ¿ (¼¿ï¾Æ»êº´¿ø) |
16:20~16:40 New trends of radiotherapy in lung cancer
À±È«ÀÎ (¼¼ºê¶õ½ºº´¿ø) |
16:45~17:00 New challenges during COVID-19
°ÀºÁÖ (°í·Á´ë±¸·Îº´¿ø) |
16:40~17:00 - Should role of surgery be re-evaluated in small cell lung cancer?
- Is there a role for surgery in stage I small cell lung cancer?
¹Ú¼º¿ë (¼¼ºê¶õ½ºº´¿ø) |
16:40~17:00 Radiotherapy for SCLC and other thoracic tumors (mesothelioma / thymoma)
°ûÀ¯° (ÀÎõ¼º¸ðº´¿ø) |
17:00~17:10 Discussion |
17:00~17:10 Discussion |
17:00~17:10 Discussion |